WO2019131308A1 - TRAITEMENT D'UNE ARYTHMIE EN FAISANT APPEL À LA 9-β-D-ARABINOFURANOSYLHYPOXANTINE - Google Patents

TRAITEMENT D'UNE ARYTHMIE EN FAISANT APPEL À LA 9-β-D-ARABINOFURANOSYLHYPOXANTINE Download PDF

Info

Publication number
WO2019131308A1
WO2019131308A1 PCT/JP2018/046477 JP2018046477W WO2019131308A1 WO 2019131308 A1 WO2019131308 A1 WO 2019131308A1 JP 2018046477 W JP2018046477 W JP 2018046477W WO 2019131308 A1 WO2019131308 A1 WO 2019131308A1
Authority
WO
WIPO (PCT)
Prior art keywords
ara
atrial fibrillation
arrhythmia
treatment
pharmaceutically acceptable
Prior art date
Application number
PCT/JP2018/046477
Other languages
English (en)
Japanese (ja)
Inventor
藤田　孝之
石川　義弘
中村　隆
敏 奥村
憲治 吹田
Original Assignee
公立大学法人横浜市立大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公立大学法人横浜市立大学 filed Critical 公立大学法人横浜市立大学
Priority to JP2019561537A priority Critical patent/JP7137852B2/ja
Publication of WO2019131308A1 publication Critical patent/WO2019131308A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • the present invention provides an antiarrhythmic drug comprising 9- ⁇ -D-arabinofuranosyl hypoxanthine, a pharmaceutically acceptable salt or solvate thereof.
  • the present invention relates to the treatment and / or treatment of arrhythmia comprising administering to a subject a pharmaceutically effective amount of 9- ⁇ -D-arabinofuranosyl hypoxanthine, a pharmaceutically acceptable salt or solvate thereof. Or provide a preventive method.
  • the present invention provides 9- ⁇ -D-arabinofuranosyl hypoxanthine, a pharmaceutically acceptable salt or solvate thereof, for the treatment and / or prevention of arrhythmia.
  • Carriers such as distilled water and physiological saline should be used when formulated into injections, and starches, lactose, sucrose, calcium carbonate etc. when formulated into capsules, tablets, powders, and granules.
  • the content of active ingredient in the formulation can be varied between 1 and 99% by weight.
  • Atrial fibrillation attack was induced by this method, and Ara-Hx (5, 10, 20 mg / kg) or DMSO only (CTRL) was intravenously administered during the stroke one minute after the onset of atrial fibrillation.
  • Ara-Hx suppresses the generation of reactive oxygen species in cardiomyocytes (FIG. 6) Reactive oxygen species in cardiomyocytes are known to be an important mechanism for the onset of atrial fibrillation and ventricular arrhythmias (JY Youn et al. J Mol Cell Cardiol 62 (2013) 72-79, AD Hafstad et al. Basic Res Cardiol 108 (2013) 359.).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouvel agent thérapeutique pour traiter une arythmie. L'invention concerne un agent anti-arythmique comprenant la 9-β-D-arabinofuranosylhypoxanthine, un sel pharmaceutiquement acceptable de celle-ci ou un solvate de celle-ci.
PCT/JP2018/046477 2017-12-27 2018-12-18 TRAITEMENT D'UNE ARYTHMIE EN FAISANT APPEL À LA 9-β-D-ARABINOFURANOSYLHYPOXANTINE WO2019131308A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019561537A JP7137852B2 (ja) 2017-12-27 2018-12-18 ９‐β‐Ｄ‐アラビノフラノシルヒポキサンチンによる不整脈治療

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017250478 2017-12-27
JP2017-250478 2017-12-27

Publications (1)

Publication Number Publication Date
WO2019131308A1 true WO2019131308A1 (fr) 2019-07-04

Family

ID=67063607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/046477 WO2019131308A1 (fr) 2017-12-27 2018-12-18 TRAITEMENT D'UNE ARYTHMIE EN FAISANT APPEL À LA 9-β-D-ARABINOFURANOSYLHYPOXANTINE

Country Status (2)

Country Link
JP (1) JP7137852B2 (fr)
WO (1) WO2019131308A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023033166A1 (fr) 2021-09-06 2023-03-09 ミライラボバイオサイエンス株式会社 Agent de traitement de cardiopathie et procédé d'atténuation d'une cardiopathie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051330A1 (fr) * 2011-10-07 2013-04-11 公立大学法人横浜市立大学 Traitement de la fibrillation auriculaire à l'aide de vidarabine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106420790A (zh) 2016-09-13 2017-02-22 北京大学 次黄嘌呤核苷酸在制备心肌力增强制剂中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051330A1 (fr) * 2011-10-07 2013-04-11 公立大学法人横浜市立大学 Traitement de la fibrillation auriculaire à l'aide de vidarabine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAMPNEY, K. J. ET AL.: "Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 62, no. 6, 1 December 1978 (1978-12-01), pages 1142 - 1153, XP055623414, ISSN: 0021-9738 *
CHEN, P. S. ET AL.: "Role of the autonomic nervous system in atrial fibrillation: Pathophysiology and Therapy", CIRCULATION RESEARCH, vol. 114, no. 9, 25 April 2014 (2014-04-25), pages 1500 - 1515, XP055300161, ISSN: 0009-7330, doi:10.1161/CIRCRESAHA.114.303772 *
DE MICHELI, A ET AL.: "Antiarrhythmic and arrhythmogenic action of inosine in experimental ventricular tachyarrhythmias", ARCHIVOS DE CARDIOLOGIA DE MEXICO, vol. 79, no. 3, July 2009 (2009-07-01), pages 175 - 181, XP055623422, ISSN: 1405-9940 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023033166A1 (fr) 2021-09-06 2023-03-09 ミライラボバイオサイエンス株式会社 Agent de traitement de cardiopathie et procédé d'atténuation d'une cardiopathie
KR20240051234A (ko) 2021-09-06 2024-04-19 미라이랩 바이오사이언스 인코퍼레이티드 심장질환용제 및 심장질환의 개선 방법

Also Published As

Publication number Publication date
JPWO2019131308A1 (ja) 2020-12-10
JP7137852B2 (ja) 2022-09-15

Similar Documents

Publication Publication Date Title
Savelieva et al. I f inhibition with ivabradine: electrophysiological effects and safety
EP0906102B1 (fr) Procede pour reguler le tonus vagal
ES2646603T3 (es) Método para tratar la fibrilación auricular
JP2002540144A (ja) 心血管及び関連病理学治療のためのピリドキシン化合物の使用
JPH09505807A (ja) プリン組成物および投与方法
KR20110026422A (ko) 영구적 심방 세동의 예방을 위한 드로네다론
KR20100135909A (ko) 심혈관성 입원 또는 사망을 예방하는데 사용하기 위한 약제의 제조에 있어서의 드로네다론의 용도
JP2012502047A (ja) 心房細動を治療する方法
US9597302B1 (en) Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation
JP2011518147A (ja) 血中カリウム濃度を調節する薬剤を調製するためのドロネダロンまたは医薬的に許容されるこの塩の使用
TWI464147B (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
WO2019131308A1 (fr) TRAITEMENT D'UNE ARYTHMIE EN FAISANT APPEL À LA 9-β-D-ARABINOFURANOSYLHYPOXANTINE
KR20110026421A (ko) 심장율동전환의 예방을 위한 드로네다론
JP2015512919A (ja) 塩酸レルカニジピンおよびロサルタンカリウム配合剤およびその調製法
JPS591415A (ja) 循環系疾患治療剤
JP2011517694A (ja) ドロネダロンと少なくとも１つの利尿薬の組み合わせおよびこの治療的使用
Thaulow et al. Role of calcium channel blockers in experimental exercise-induced ischemia
KR20160020411A (ko) 빈맥성부정맥 및 고혈압의 장기 치료에서 란디오롤 하이드로클로라이드의 용도
JP6028983B2 (ja) ビダラビンによる心房細動治療
WO2012020377A1 (fr) Utilisation du dronédarone pour la préparation d'un médicament destiné à maîtriser le rythme et la fréquence chez des patients atteints de fibrillation auriculaire
Tai et al. Sinomenine
JP2010248263A (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
Shen et al. Sodium channel enhancer restores baroreflex sensitivity in conscious dogs with heart failure
RU2248208C2 (ru) Пуринрибозиды в качестве антиаритмических средств
JP2004508336A (ja) 抗不整脈薬としてのプリンリボシド

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18895162

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019561537

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18895162

Country of ref document: EP

Kind code of ref document: A1